Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 1
1990 3
1991 5
1992 13
1993 27
1994 41
1995 53
1996 90
1997 95
1998 108
1999 124
2000 140
2001 182
2002 170
2003 143
2004 171
2005 160
2006 167
2007 167
2008 149
2009 127
2010 153
2011 144
2012 152
2013 131
2014 149
2015 150
2016 128
2017 128
2018 135
2019 127
2020 119
2021 153
2022 113
2023 115
2024 38

Text availability

Article attribute

Article type

Publication date

Search Results

3,723 results

Results by year

Filters applied: . Clear all
Page 1
Topotecan in cervical cancer.
Ackermann S, Beckmann MW, Thiel F, Bogenrieder T. Ackermann S, et al. Int J Gynecol Cancer. 2007 Nov-Dec;17(6):1215-23. doi: 10.1111/j.1525-1438.2007.01003.x. Int J Gynecol Cancer. 2007. PMID: 17997795 Review.
We therefore conducted a systematic review on the studies using topotecan in cervical cancer. Seven phase I-III clinical trials using topotecan, both as a single agent and in combination with cisplatin or paclitaxel, in patients with recurrent or advanced carcinoma …
We therefore conducted a systematic review on the studies using topotecan in cervical cancer. Seven phase I-III clinical trials using …
Topotecan Liposomes: A Visit from a Molecular to a Therapeutic Platform.
Saraf S, Jain A, Hurkat P, Jain SK. Saraf S, et al. Crit Rev Ther Drug Carrier Syst. 2016;33(5):401-432. doi: 10.1615/CritRevTherDrugCarrierSyst.2016015926. Crit Rev Ther Drug Carrier Syst. 2016. PMID: 27910741 Review.
Topotecan (TPT), a potent anticancer camptothecin analog, is well described for the treatment of ovarian cancer, but has also anticancer activity against small-cell and non-small-cell lung cancer, breast cancer, and acute leukemia. ...
Topotecan (TPT), a potent anticancer camptothecin analog, is well described for the treatment of ovarian cancer, but has also antican …
Topotecan: a review of its efficacy in small cell lung cancer.
Ormrod D, Spencer CM. Ormrod D, et al. Drugs. 1999 Sep;58(3):533-51. doi: 10.2165/00003495-199958030-00020. Drugs. 1999. PMID: 10493279 Review.
The tolerability and compliance advantages of oral topotecan may make this the route of choice in the future. Noncumulative anaemia, neutropenia and thrombocytopenia are the dose-limiting adverse effects associated with topotecan. CAV and topotecan therapy ha …
The tolerability and compliance advantages of oral topotecan may make this the route of choice in the future. Noncumulative anaemia, …
Topotecan for relapsed small cell lung cancer: a systematic review and economic evaluation.
Hartwell D, Jones J, Loveman E, Harris P, Clegg A, Bird A. Hartwell D, et al. Cancer Treat Rev. 2011 May;37(3):242-9. doi: 10.1016/j.ctrv.2010.07.005. Epub 2010 Aug 14. Cancer Treat Rev. 2011. PMID: 20709456 Review.
BACKGROUND: Topotecan is a relatively new drug for use as a second-line treatment in patients with relapsed small cell lung cancer (SCLC). ...The clinical evidence indicates a statistically significant benefit of oral topotecan plus BSC compared to BSC alone for ove …
BACKGROUND: Topotecan is a relatively new drug for use as a second-line treatment in patients with relapsed small cell lung cancer (S …
Topotecan in the management of cervical cancer.
Randall-Whitis LM, Monk BJ. Randall-Whitis LM, et al. Expert Opin Pharmacother. 2007 Feb;8(2):227-36. doi: 10.1517/14656566.8.2.227. Expert Opin Pharmacother. 2007. PMID: 17257092 Review.
Topotecan, a semisynthetic camptothecin, exerts its cytotoxic effect through inhibition of DNA topoisomerase I. Single-agent topotecan has demonstrated activity against persistent, metastatic and recurrent cancer of the uterine cervix. ...
Topotecan, a semisynthetic camptothecin, exerts its cytotoxic effect through inhibition of DNA topoisomerase I. Single-agent topot …
A real-world data analysis of topotecan in the FDA Adverse Event Reporting System (FAERS) database.
Yang H, Wan Z, Chen M, Zhang X, Cui W, Zhao B. Yang H, et al. Expert Opin Drug Metab Toxicol. 2023 Apr;19(4):217-223. doi: 10.1080/17425255.2023.2219390. Epub 2023 May 30. Expert Opin Drug Metab Toxicol. 2023. PMID: 37243615
METHODS: To assess the disproportionality of topotecan-related AEs in real-world data, four algorithms (ROR, PRR, BCPNN, and EBGM) were employed as measures to detect signals of topotecan-associated AEs. ...Among these reports, 1,896 were identified as primary suspe …
METHODS: To assess the disproportionality of topotecan-related AEs in real-world data, four algorithms (ROR, PRR, BCPNN, and EBGM) we …
Ocular pharmacology of topotecan and its activity in retinoblastoma.
Schaiquevich P, Carcaboso AM, Buitrago E, Taich P, Opezzo J, Bramuglia G, Chantada GL. Schaiquevich P, et al. Retina. 2014 Sep;34(9):1719-27. doi: 10.1097/IAE.0000000000000253. Retina. 2014. PMID: 25099219 Review.
Topotecan administered intraophthalmic artery shows higher passage to the vitreous compared with periocular administration in a swine model. CONCLUSION: Topotecan alone or in combination is active against retinoblastoma. ...
Topotecan administered intraophthalmic artery shows higher passage to the vitreous compared with periocular administration in a swine …
Topotecan - A novel topoisomerase I inhibitor: pharmacology and clinical experience.
Kollmannsberger C, Mross K, Jakob A, Kanz L, Bokemeyer C. Kollmannsberger C, et al. Oncology. 1999;56(1):1-12. doi: 10.1159/000011923. Oncology. 1999. PMID: 9885371 Review.
Other topotecan administration schedules are currently being investigated. ...Results of phase II studies suggest considerable antitumor activity of single agent topotecan in small cell lung cancer and ovarian cancer patients. A randomized phase III trial of topo …
Other topotecan administration schedules are currently being investigated. ...Results of phase II studies suggest considerable antitu …
Topotecan dosing guidelines in ovarian cancer: reduction and management of hematologic toxicity.
Armstrong DK. Armstrong DK. Oncologist. 2004;9(1):33-42. doi: 10.1634/theoncologist.9-1-33. Oncologist. 2004. PMID: 14755013 Free article. Review.
Reducing the starting topotecan dose to 1.0 or 1.25 mg/m2/day is recommended to reduce the incidence of severe myelosuppression in high-risk individuals receiving topotecan for 5 consecutive days. ...Proposed topotecan dosing guidelines to reduce and manage m …
Reducing the starting topotecan dose to 1.0 or 1.25 mg/m2/day is recommended to reduce the incidence of severe myelosuppression in hi …
3,723 results

Searches related to "topotecan"